<DOC>
	<DOCNO>NCT00006145</DOCNO>
	<brief_summary>Cytomegalovirus ( CMV ) infection common opportunistic infection ( OI ) HIV patient . The purpose study find whether valganciclovir , antiviral approve FDA treatment CMV eye , safe effective prevent CMV organ damage people HIV .</brief_summary>
	<brief_title>Preventing Cytomegalovirus ( CMV ) Organ Damage With Valganciclovir People With HIV</brief_title>
	<detailed_description>CMV infection , commonly retina ( also know CMV retinitis ) , common OI observe HIV patient . Despite treatment , CMV retinitis result severe visual impairment CMV disease associate reduce survival time . HIV patient receive highly active antiretroviral therapy ( HAART ) HIV infection CD4 count less 100 cells/mm3 may increase risk CMV infection complication . Valganciclovir approve FDA March 29 , 2001 treatment symptom CMV retinitis patient weaken immune system , include people HIV AIDS . This study evaluate safety efficacy valganciclovir prevent CMV organ damage HIV patient . This study last approximately 6 year . Step 1 longitudinal screen phase study . Patients high risk CMV disease enrol study screen every 8 week CMV blood ; medical history assessment , physical examination , blood work occur visit . Additional blood collection monitor HIV infection occur every 16 week . Patients undergo opthalmologic examination every 24 week . Patients develop detectable CMV blood Step 1 enter Step 2 study . In version 3.0 study , participant test positive CMV viremia currently Step 2 automatically enrolled Step 4 randomly assign one two group : 1 ) 900 mg valganciclovir twice daily 3 week , follow 900 mg valganciclovir daily , 2 ) placebo . Participants enter Step 3 develop CMV end-organ disease , point participant offer 900 mg valganciclovir twice daily 3 week , 900 valganciclovir daily thereafter .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Note : Per recommendation NIAID Therapeutic Trials Data Safety Monitoring Board ( DSMB ) , trial close 10/03/05 . The DSMB determine study reach primary objective . All participant valganciclovir must complete study evaluation 08/31/05 ; participant take valganciclovir must complete study evaluation 10/03/05 . Inclusion Criteria Step 1 : HIV infect Viral load great 400 copies/ml CD4 count le 100 cells/mm3 Have take HAART 3 month longer OR take HAART plan start HAART least 3 month study entry Have serum CMV IgG antibody Have consent parent guardian 18 year age Willing use acceptable form contraception Exclusion Criteria Step 1 : History CMV endorgan disease Certain antiviral drug CMV prophylaxis within 8 week study entry Pregnant breastfeeding Currently require ongoing foscarnet cidofovir . Limited course foscarnet cidofovir treatment disease CMV permit approve protocol chair .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Polymerase Chain Reaction</keyword>
	<keyword>Viremia</keyword>
	<keyword>DNA , Viral</keyword>
</DOC>